Charlien Berghen
Katholieke Universiteit Leuven
DissectionInternal medicineRadiologyUrologySurgerySeries (stratigraphy)OncologyBiochemical recurrenceAndrogen deprivation therapyMetastasectomyMetastasisProstatectomyProstate cancerLymph nodeRecurrent prostate cancerIn patientPost prostatectomySalvage radiationRadiation therapyTerm (time)Medicine
52Publications
5H-index
59Citations
Publications 59
Newest
#1G. GandagliaH-Index: 3
#2Axel HeidenreichH-Index: 73
view all 23 authors...
Source
#1Charlien BerghenH-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. G. De MeerleerH-Index: 9
view all 8 authors...
Source
#1Gaëtan Devos (Katholieke Universiteit Leuven)H-Index: 6
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
Last. Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
view all 12 authors...
Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer...
Source
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 8 authors...
Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective e...
Source
#1N. FossatiH-Index: 5
Last. Elio MazzoneH-Index: 15
view all 25 authors...
Source
#1N. FossatiH-Index: 5
Last. Elio MazzoneH-Index: 15
view all 25 authors...
Source
#1Gaëtan DevosH-Index: 6
Last. S. JoniauH-Index: 6
view all 12 authors...
Source
#1Gaëtan DevosH-Index: 6
Last. S. JoniauH-Index: 6
view all 12 authors...
Source
#1Daniele RobestiH-Index: 8
#2N. FossatiH-Index: 5
Last. B. Noris ChiordaH-Index: 1
view all 26 authors...
Source
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 11 authors...
BACKGROUND: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2-3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressive lesions while other metastases are still controlled by ongoing systemic treatment. METHODS: In this single arm prospective phase II trial, we aim to include 18 patients with oligoprogressive mCRPC (...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.